A phase I study of M7824, a first-in-class bifunctional antibody targeting TGF-βRII and PD-L1, in heavily pretreated, advanced solid carcinoma patients showed a manageable safety profile and signs of efficacy.42 There are multiple ongoing clinical trials involving M7824 in combination with standard of care in breast cancer (with radiation, NCT03524170; with eribulin, NCT03579472; in a neoadjuvant window study, NCT03620201). The gene discussed is CD274; the disease is breast carcinoma.